Skip to main content
SpringerLink
Log in

Metaanalysis of Tirilazad Mesylate in Patients with Aneurysmal Subarachnoid Hemorrhage

  • Review
  • Published:
Neurocritical Care Aims and scope Submit manuscript

Abstract

Background

Tirilazad is a non-glucocorticoid, 21-aminosteriod that inhibits lipid peroxidation. It had neuroprotective effects in experimental ischemic stroke and reduced angiographic vasospasm after experimental subarachnoid hemorrhage (SAH). Five randomized clinical trials of tirilazad were conducted in patients with SAH. We performed a meta-analysis of these trials to assess the effect of tirilazad on unfavorable outcome, symptomatic vasospasm, and cerebral infarction after SAH.

Methods

Data from 3,797 patients were analyzed and modeled using random effect and Mantel-Haenszel meta-analyses and multivariable logistic regression to determine the effect of tirilazad on clinical outcome, symptomatic vasospasm, and cerebral infarction. Clinical outcome was assessed 3 months after SAH using the Glasgow outcome scale, and symptomatic vasospasm was defined by clinical criteria with laboratory and radiological exclusion of other causes of neurological deterioration.

Results

The five trials were randomized, double-blind, and placebo-controlled. Tirilazad did not significantly decrease unfavorable clinical outcome on the GOS (odds ratio [OR] 1.04, 95% confidence interval [CI] 0.89–1.20) or cerebral infarction (OR 1.04, 95% CI 0.89–1.22). There was a significant reduction in symptomatic vasospasm in patients treated with tirilazad (OR 0.80, 95% CI 0.69–0.93). There was no heterogeneity across the five trials.

Conclusion

Tirilazad had no effect on clinical outcome but did decrease symptomatic vasospasm in five trials of aneurysmal SAH. The dissociation between clinical outcome and symptomatic vasospasm deserves further investigation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Hall ED. Inhibition of lipid peroxidation in central nervous system trauma and ischemia. J Neurol Sci. 1995;134(Suppl):79–83. doi:10.1016/0022-510X(95)00211-J.

    Article  PubMed  Google Scholar 

  2. Haley EC Jr, Kassell NF, Alves WM, Weir BK, Hansen CA. Phase II trial of tirilazad in aneurysmal subarachnoid hemorrhage. A report of the Cooperative Aneurysm Study. J Neurosurg. 1995;82:786–90.

    PubMed  Google Scholar 

  3. Kassell NF, Haley ECJ, Apperson-Hansen C, Alves WM. Randomized, double-blind, vehicle-controlled trial of tirilazad mesylate in patients with aneurysmal subarachnoid hemorrhage: a cooperative study in Europe, Australia, and New Zealand. J Neurosurg. 1996;84:221–8.

    PubMed  CAS  Google Scholar 

  4. Haley EC Jr, Kassell NF, Apperson-Hansen C, Maile MH, Alves WM. A randomized, double-blind, vehicle-controlled trial of tirilazad mesylate in patients with aneurysmal subarachnoid hemorrhage: a cooperative study in North America. J Neurosurg. 1997;86:467–74.

    PubMed  CAS  Google Scholar 

  5. Lanzino G, Kassell NF. Double-blind, randomized, vehicle-controlled study of high-dose tirilazad mesylate in women with aneurysmal subarachnoid hemorrhage. Part II. A cooperative study in North America. J Neurosurg. 1999;90:1018–24.

    Article  PubMed  CAS  Google Scholar 

  6. Lanzino G, Kassell NF, Dorsch NW, et al. Double-blind, randomized, vehicle-controlled study of high-dose tirilazad mesylate in women with aneurysmal subarachnoid hemorrhage. Part I. A cooperative study in Europe, Australia, New Zealand, and South Africa. J Neurosurg. 1999;90:1011–7.

    PubMed  CAS  Google Scholar 

  7. Dorsch NW, Kassell NF, Sinkula MS. Metaanalysis of trials of tirilazad mesylate in aneurysmal SAH. Acta Neurochir Suppl (Wien). 2001;77:233–5.

    CAS  Google Scholar 

  8. Jennett B, Bond M. Assessment of outcome after severe brain damage. A practical scale. Lancet. 1975;1:480–4. doi:10.1016/S0140-6736(75)92830-5.

    Article  PubMed  CAS  Google Scholar 

  9. Teasdale G, Jennett B. Assessment of impaired consciousness and coma: a practical scale. Lancet. 1974;2:81–4. doi:10.1016/S0140-6736(74)91639-0.

    Article  PubMed  CAS  Google Scholar 

  10. Brott T, Adams HP Jr, Olinger CP, et al. Measurements of acute cerebral infarction: a clinical examination scale. Stroke. 1989;20:864–70.

    PubMed  CAS  Google Scholar 

  11. Rosengart AJ, Schultheiss KE, Tolentino J, Macdonald RL. Prognostic factors for outcome in patients with aneurysmal subarachnoid hemorrhage. Stroke. 2007;38:2315–21. doi:10.1161/STROKEAHA.107.484360.

    Article  PubMed  Google Scholar 

  12. Rosengart AJ, Huo JD, Tolentino J, et al. Outcome in patients with subarachnoid hemorrhage treated with antiepileptic drugs. J Neurosurg. 2007;107:253–60. doi:10.3171/JNS-07/08/0253.

    Article  PubMed  Google Scholar 

  13. Fisher M, Albers GW, Donnan GA, et al. Enhancing the development and approval of acute stroke therapies: stroke therapy academic industry roundtable. Stroke. 2005;36:1808–13. doi:10.1161/01.STR.0000173403.60553.27.

    Article  PubMed  Google Scholar 

  14. Guillemin F. Primer: the fallacy of subgroup analysis. Nat Clin Pract Rheumatol. 2007;3:407–13. doi:10.1038/ncprheum0528.

    Article  PubMed  Google Scholar 

  15. Murray GD, Barer D, Choi S, et al. Design and analysis of phase 3 trials with ordered outcome scales: the concept of the sliding dichotomy. J Neurotrauma. 1995;22:511–7. doi:10.1089/neu.2005.22.511.

    Article  Google Scholar 

  16. Saver JL. Novel end point analytic techniques and interpreting shifts across the entire range of outcome scales in acute stroke trials. Stroke. 2007;38:3055–62. doi:10.1161/STROKEAHA.107.488536.

    Article  PubMed  Google Scholar 

  17. Glick H, Willke R, Polsky D, et al. Economic analysis of tirilazad mesylate for aneurysmal subarachnoid hemorrhage. Economic evaluation of a phase III clinical trial in Europe and Australia. Int J Technol Assess Health Care. 1998;14:145–60.

    PubMed  CAS  Google Scholar 

  18. Fergusen S, Macdonald RL. Predictors of cerebral infarction in patients with aneurysmal subarachnoid hemorrhage. Neurosurgery. 2007;60:658–67. doi:10.1227/01.NEU.0000255396.23280.31.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Neurosurgery, Keenan Research Centre in the Li Ka Shing Knowledge Institute of St. Michael’s Hospital, University of Toronto, 30 Bond Street, Toronto, ON, Canada, M5B 1W8

    Yeon Gyoe Jang, Don Ilodigwe & R. Loch Macdonald

  2. Department of Surgery, University of Toronto, Toronto, ON, Canada, M5B 1W8

    R. Loch Macdonald

Authors
  1. Yeon Gyoe Jang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Don Ilodigwe
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. R. Loch Macdonald
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to R. Loch Macdonald.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Jang, Y.G., Ilodigwe, D. & Macdonald, R.L. Metaanalysis of Tirilazad Mesylate in Patients with Aneurysmal Subarachnoid Hemorrhage. Neurocrit Care 10, 141–147 (2009). https://doi.org/10.1007/s12028-008-9147-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12028-008-9147-y

Keywords

Search

Navigation